Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1All patients in the study will be treated with ocrelizumab1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
2Continued Ocrelizumab1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
3Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab12件: Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide		10件: D01370 ,
D02802 ,
D02994 ,
D03846 ,
D05218 (Name: Ocrelizumab),
D06886 ,
D09314 ,
D10001 ,
D10172 ,
D11215 		7件: CD52,
DHODH,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬		31件: , Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬1件: 13
4OCRELIZUMAB1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬3件: 13, 46, 49
5Ocrelizumab (CinnaGen, Iran)1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
6Ocrelizumab (Roche, Switzerland)1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
7Ocrelizumab / rhuMAb 2H71件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
8Ocrelizumab 300 mg1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
9Ocrelizumab 300mg1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
10Ocrelizumab 300mg /10ml1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
11Ocrelizumab 300mg/10 ml1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
12Ocrelizumab 300mg/10ml1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
13Ocrelizumab 500mg1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
14Ocrelizumab 600 mg1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
15Ocrelizumab at home1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
16Ocrelizumab Dose 11件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
17Ocrelizumab Dose 2 and Dose 31件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
18Ocrelizumab IV1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
19Ocrelizumab SC1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
20Ocrelizumabu 200mg----1件: 46
21Ocrelizumabu 50mg----1件: 46
22Perfusion of treatment Ocrelizumab1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
23Short-course Ocrelizumab1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13